MedTrace Logo

Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV

NCT03858907 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2019-03-01

No results posted yet for this study

Summary

To evaluate the Quantiferon-CMV test ability to predict occurrence of cytomegalovirus (CMV) disease o treated infection after kidney transplantation. Patients studied are those already infected by CMV before transplantation ("seropositive"). Patients given thymoglobulin as induction therapy receive CMV prophylaxis with valganciclovir, while those given basiliximab undergo weekly monitoring for CMV viremia with preemptive treatment as needed.

Conditions

  • Cytomegalovirus Infections
  • CMV
  • Kidney Transplant Infection

Sponsors & Collaborators

  • University of Sao Paulo General Hospital

    lead OTHER

Principal Investigators

  • Elias David-Neto, MD, PhD · Instituto do Coracao

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-05
Primary Completion
2020-08-05
Completion
2020-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03858907 on ClinicalTrials.gov